{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:13:58Z","timestamp":1768882438885,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12185-025-04091-0","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:50:53Z","timestamp":1761558653000},"page":"141-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7623-1900","authenticated-orcid":false,"given":"Yui","family":"Chikagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoomi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nukii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Mura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichiro","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yoroidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Imi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Zaimoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyo","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"12","key":"4091_CR1","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1111\/cas.15996","volume":"114","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, et al. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B-cell lymphoma. Cancer Sci. 2023;114(12):4643\u201353.","journal-title":"Cancer Sci"},{"issue":"12","key":"4091_CR2","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41(12):2238\u201347.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4091_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong EA, Ruella M, Schuster SJ. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy. N Engl J Med. 2021;384(7):673\u20134.","journal-title":"N Engl J Med"},{"issue":"6","key":"4091_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/modpathol.2015.42","volume":"28","author":"Y Li","year":"2015","unstructured":"Li Y, Hu S, Zuo Z, Hong M, Lin P, Li S, et al. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol. 2015;28(6):787\u201398.","journal-title":"Mod Pathol"},{"issue":"3","key":"4091_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/pin.12145","volume":"64","author":"H Miyoshi","year":"2014","unstructured":"Miyoshi H, Sato K, Yoshida M, Kimura Y, Kiyasu J, Ichikawa A, et al. CD5-positive follicular lymphoma characterized by CD25, MUM1, low frequency of t(14;18) and poor prognosis. Pathol Int. 2014;64(3):95\u2013103.","journal-title":"Pathol Int"},{"issue":"24","key":"4091_CR6","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1182\/blood.2022016945","volume":"140","author":"R Di Blasi","year":"2022","unstructured":"Di Blasi R, Le Gouill S, Bachy E, Cartron G, Beauvais D, Le Bras F, et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022;140(24):2584\u201393.","journal-title":"Blood"},{"key":"4091_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, et al. Duobody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625.","journal-title":"EBioMedicine"},{"issue":"12","key":"4091_CR8","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia. 2024;38(12):2653\u201362.","journal-title":"Leukemia"},{"issue":"1","key":"4091_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjh.17121","volume":"192","author":"F Lutfi","year":"2021","unstructured":"Lutfi F, Holtzman N, Siglin J, Bukhari A, Mustafa Ali M, Kim D, et al. Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed\/refractory large B-cell lymphoma. Br J Haematol. 2021;192(1):212\u20136.","journal-title":"Br J Haematol"},{"issue":"10","key":"4091_CR10","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140(10):1104\u201318.","journal-title":"Blood"},{"issue":"3","key":"4091_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3324\/haematol.2023.283758","volume":"109","author":"M Casey","year":"2024","unstructured":"Casey M, Lee C, Kwok WY, Law SC, Corvino D, Gandhi MK, et al. Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy. Haematologica. 2024;109(3):787\u201398.","journal-title":"Haematologica"},{"issue":"1","key":"4091_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3324\/haematol.2022.281242","volume":"108","author":"J Zurko","year":"2023","unstructured":"Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023;108(1):98\u2013109.","journal-title":"Haematologica"},{"issue":"2","key":"4091_CR13","first-page":"99","volume":"29","author":"S Fried","year":"2023","unstructured":"Fried S, Shouval R, Walji M, Flynn JR, Yerushalmi R, Shem-Tov N, et al. Allogeneic hematopoietic cell transplantation after chimeric antigen receptor T cell therapy in large B cell lymphoma. Transpl Cell Ther. 2023;29(2):99\u2013107.","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"4091_CR14","first-page":"750","volume":"29","author":"P Derigs","year":"2023","unstructured":"Derigs P, Bethge WA, Kr\u00e4mer I, Holtick U, von Tresckow B, Ayuk F, et al. Long-term survivors after failure of chimeric antigen receptor T cell therapy for large B cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation analysis. Transpl Cell Ther. 2023;29(12):750\u20136.","journal-title":"Transpl Cell Ther"},{"issue":"11","key":"4091_CR15","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41409-023-02069-2","volume":"58","author":"M Pe\u00f1a","year":"2023","unstructured":"Pe\u00f1a M, Montan\u00e9 C, Paviglianiti A, Hurtado L, Gonz\u00e1lez S, Carro I, et al. Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas. Bone Marrow Transpl. 2023;58(11):1282\u20135.","journal-title":"Bone Marrow Transpl"},{"issue":"13","key":"4091_CR16","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1182\/bloodadvances.2024012916","volume":"8","author":"GK Reynolds","year":"2024","unstructured":"Reynolds GK, Maclean M, Cliff ERS, Teh BW, Thursky KA, Slavin MA, et al. Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood Adv. 2024;8(13):3555\u20139.","journal-title":"Blood Adv"},{"issue":"3","key":"4091_CR17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/bloodadvances.2024014781","volume":"9","author":"N Desai","year":"2025","unstructured":"Desai N, Altareb M, Remberger M, Chen C, Alfaro Moya T, Al-Shaibani E, et al. PTcy-based graft-versus-host disease prophylaxis for matched sibling donor allogeneic hematopoietic cell transplantation. Blood Adv. 2025;9(3):660\u20139.","journal-title":"Blood Adv"},{"issue":"23","key":"4091_CR18","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1182\/blood.2020009362","volume":"137","author":"SR Goldsmith","year":"2021","unstructured":"Goldsmith SR, Abid MB, Auletta JJ, Bashey A, Beitinjaneh A, Castillo P, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021;137(23):3291\u2013305.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04091-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04091-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:03:16Z","timestamp":1768834996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04091-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4091"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04091-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hirohito Yamazaki and Yoshitaka Zaimoku serve as editors of the International Journal of Hematology. All other authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}